Formulation and Evaluation of Orodispersible Tablets of Pyrimethamine

Background: Toxoplasmosis is an opportunistic infection. It is caused by Toxoplasma gondii, which affects the eye, central nervous system and other body systems. It is common in paediatric, geriatric, and patients who are immune-compromised. It results from poor hygiene and improper handling of cats' faeces. Objectives: The treatment of toxoplasmosis typically involves pyrimethamine with folinic acid and other supportive agents. In the current research project, ODT formulations of pyrimethamine have been formulated in three types, namely C1, C2, and C3. These three formulations differ from one another based on the kind of disintegrants used. Methodology: The direct compression method was used for formulating the ODT. Different parameters of the formulated product were studied in its three formulations, C1, C2, and C3. Pre-compression evaluation, including FTIR spectroscopy and other methods, was conducted. Post-compression evaluation, including content assay, dissolution, and stability profile under ambient conditions, was monitored. Results: All official tests complied with the orodispersible tablet specifications outlined by the British Pharmacopoeia (B.P.) and the United States Pharmacopoeia (USP). However, notable differences were observed among the three formulations—C1, C2, and C3 in specific evaluated parameters, indicating variability in performance depending on the formulation components. Conclusion: The use of different disintegration agents resulted in slight variations in tablet behavior. Nevertheless, all formulations met key orodispersible criteria and demonstrated favorable characteristics for patient compliance, particularly for individuals with swallowing difficulties.